Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.
Diabetic Retinopathy: Focus On Diabetic Macular Edema
To provide ophthalmologists, endocrinologists, diabetologists, and primary care physicians with up-to-date information on the diagnosis and treatment of patients with diabetic retinopathy.
This activity is designed for ophthalmologists, endocrinologists, diabetologists, and primary care physicians. No prerequisites required.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. At the conclusion of this activity, the participant should be able to:
- Describe the molecular biology underlying diabetic retinopathy (DR) in general and
diabetic macular edema (DME) in particular.
- Establish the role of the ophthalmologist in the prevention, detection, and treatment of DR, and specifically DME, both through direct patient care and through interaction with other healthcare providers.
- Assess the diagnosis, classification, and monitoring of DME and the latest strategies aimed at its prevention and treatment.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The estimated time to complete this educational activity: 2 hours.
Release date: March 15, 2006. Expiration date: March 15, 2008.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
This program is supported by an educational grant from Eli Lilly and Company.
Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:
Julia A. Haller, MD
Katharine Graham Professor of Ophthalmology
Wilmer Eye Institute
Johns Hopkins University School of Medicine
• Dr Haller reports having no financial or advisory relationships with corporate organizations related to this activity.
Lloyd P. Aiello, MD, PhD
Associate Professor of Ophthalmology
Harvard Medical School
Director, Beetham Eye Institute
Joslin Diabetes Center
• Dr Aiello reports serving as a consultant to and receiving honoraria from Eli Lilly and Company and Eyetech.
Frederick L. Ferris III, MD
Director of Clinical Research and Epidemiology
National Eye Institute
National Institutes of Health
• Dr Ferris reports having no financial or advisory relationhips with corporate organizations related to this activity.
George A. Williams, MD
Chair, Department of Ophthalmology
William Beaumont Hospital
Director, Beaumont Eye Institute
Royal Oak, Michigan
• Dr Williams reports having no financial or advisory relationships with corporate organizations related to this activity.
Notice: The audience is advised that articles in this CME activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.
Dr Aiello–protein kinase C inhibitors and steroids.
Dr Ferris–bevacizumab, intravitreal steroids, pegaptanib, ranibizumab, and ruboxistaurin.
All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.
Advanced Studies in Ophthalmology provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Ophthalmology does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.